PL438355A1 - Sól imidazoliowa, będąca pochodną kwasu litocholowego, sposób jej wytwarzania oraz jej zastosowania - Google Patents

Sól imidazoliowa, będąca pochodną kwasu litocholowego, sposób jej wytwarzania oraz jej zastosowania

Info

Publication number
PL438355A1
PL438355A1 PL438355A PL43835521A PL438355A1 PL 438355 A1 PL438355 A1 PL 438355A1 PL 438355 A PL438355 A PL 438355A PL 43835521 A PL43835521 A PL 43835521A PL 438355 A1 PL438355 A1 PL 438355A1
Authority
PL
Poland
Prior art keywords
sub
imidazolium salt
lithocholic acid
acid derivative
preparation
Prior art date
Application number
PL438355A
Other languages
English (en)
Inventor
Diana SAWICKA
Agnieszka Hryniewicka
Halina CAR
Jacek MORZYCKI
Original Assignee
Uniwersytet Medyczny W Białymstoku
Uniwersytet W Białymstoku
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Medyczny W Białymstoku, Uniwersytet W Białymstoku filed Critical Uniwersytet Medyczny W Białymstoku
Priority to PL438355A priority Critical patent/PL438355A1/pl
Priority to EP22758011.5A priority patent/EP4366740A1/en
Priority to PCT/IB2022/056197 priority patent/WO2023281388A1/en
Publication of PL438355A1 publication Critical patent/PL438355A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/58—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Przedmiotem wynalazku jest sól imidazoliowa, będąca pochodną kwasu litocholowego, o wzorze strukturalnym 1: przy czym X jest wybrany z grupy obejmującej: I, Br, Cl, oraz R jest wybrany z grupy obejmującej nierozgałęzione i rozgałęzione grupy alkilowe: -CH<sub>3</sub>, -C<sub>2</sub>H<sub>5</sub>, -C<sub>3</sub>H<sub>8</sub>, -C<sub>4</sub>H<sub>9</sub>, -C<sub>5</sub>H<sub>11</sub>, -C<sub>6</sub>H<sub>13</sub>, -C<sub>7</sub>H<sub>15</sub>, -C<sub>8</sub>H<sub>17</sub>, -C<sub>12</sub>H<sub>25</sub>, -C<sub>16</sub>H<sub>33</sub>, do zastosowania w leczeniu nowotworu. Kolejnymi przedmiotami wynalazku są sól imidazoliowa, będąca pochodną kwasu litocholowego, o wzorze strukturalnym, przy czym X jest wybrany z grupy obejmującej: I, Br Cl, oraz R jest wybrany z grupy obejmującej nierozgałęzione i rozgałęzione grupy alkilowe: -C<sub>3</sub>H<sub>8</sub>, -C<sub>4</sub>H<sub>9</sub>, -C<sub>7</sub>H<sub>15</sub>, -C<sub>8</sub>H<sub>17</sub>, -C<sub>12</sub>H<sub>25</sub>, -C<sub>16</sub>H<sub>33</sub>, sposób wytwarzania soli imidazoliowej według wynalazku oraz jej zastosowanie jako lek.
PL438355A 2021-07-05 2021-07-05 Sól imidazoliowa, będąca pochodną kwasu litocholowego, sposób jej wytwarzania oraz jej zastosowania PL438355A1 (pl)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PL438355A PL438355A1 (pl) 2021-07-05 2021-07-05 Sól imidazoliowa, będąca pochodną kwasu litocholowego, sposób jej wytwarzania oraz jej zastosowania
EP22758011.5A EP4366740A1 (en) 2021-07-05 2022-07-05 Imidazolium salt, which is a derivative of lithocholic acid, a method of its preparation and its use
PCT/IB2022/056197 WO2023281388A1 (en) 2021-07-05 2022-07-05 Imidazolium salt, which is a derivative of lithocholic acid, a method of its preparation and its use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL438355A PL438355A1 (pl) 2021-07-05 2021-07-05 Sól imidazoliowa, będąca pochodną kwasu litocholowego, sposób jej wytwarzania oraz jej zastosowania

Publications (1)

Publication Number Publication Date
PL438355A1 true PL438355A1 (pl) 2023-01-09

Family

ID=83005941

Family Applications (1)

Application Number Title Priority Date Filing Date
PL438355A PL438355A1 (pl) 2021-07-05 2021-07-05 Sól imidazoliowa, będąca pochodną kwasu litocholowego, sposób jej wytwarzania oraz jej zastosowania

Country Status (3)

Country Link
EP (1) EP4366740A1 (pl)
PL (1) PL438355A1 (pl)
WO (1) WO2023281388A1 (pl)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2249832A4 (en) * 2008-01-30 2011-12-21 Agency Science Tech & Res METHOD FOR THE TREATMENT OF FIBROSIS AND CANCER WITH IMIDAZOLIUM AND IMIDAZOLINI COMPOUNDS
PL237764B1 (pl) * 2018-06-28 2021-05-31 Univ W Bialymstoku Steroidowa sól imidazoliowa, sposoby jej wytwarzania oraz jej zastosowania

Also Published As

Publication number Publication date
WO2023281388A1 (en) 2023-01-12
EP4366740A1 (en) 2024-05-15

Similar Documents

Publication Publication Date Title
MX2022006033A (es) Lipidos ionizables y composiciones de nanoparticulas de estos.
RU2495044C2 (ru) Ингибиторы активности протеинтирозинкиназы
PH12021552782A1 (en) Modulators of thr-㟠and methods of use thereof
EP4660303A3 (en) Pcsk9 antagonist compounds
SA523442662B1 (ar) Apol1 مثبطات لـ وطرق استخدامها
EA201390840A1 (ru) Полициклический lpaантагонист и его применение
CR20240312A (es) Macrociclos de imidazol para el tratamiento de enfermedades autoinmunitarias
GEAP202416543A (en) 4-phenyl-2-(1h-1,2,3-triazol-4-yl)piperidin-4-ol derivatives as inhibitors of apol1 and methods of using same
EA200870321A1 (ru) Способ получения 4-оксохинолинового соединения
MX389965B (es) Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos
CY1111980T1 (el) Παραγωγα του αμιδιου τα οποια φερουν ενα υποκαταστατο του κυκλοπροπυλαμινοκαρβονυλιου και χρησιμευουν ως αναστολεις κυτταροκινης
MX2020008816A (es) Derivados de triazina para el tratamiento de enfermedades relacionadas con neurotrofinas.
AR116022A1 (es) Compuestos heteroaromáticos como inhibidores de vanina
MX2021012223A (es) Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria.
MX2019013562A (es) Compuestos de anilina heteroaromatica o fusionados para el tratamiento de trastornos dermicos.
MX2025010256A (es) Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno
CY1107519T1 (el) Yποκατεστημενες χαλκονες ως θepαπευτικες ενωσεις
MX2022010957A (es) Compuestos que se dirigen a las proteínas de unión al arn o a las proteínas modificadoras del arn.
EA201892460A1 (ru) Производные аденина как ингибиторы протеинкиназ
RU2014129937A (ru) Способы и промежуточные соединения для получения фармацевтических агентов
MX2021007511A (es) Procedimiento para la preparacion de anilinas sustituidas.
NZ600157A (en) Sustained-release formulation comprising metastin derivative
WO2018109504A8 (en) N-OXIDE HETEROCYCLES FOR USE IN THE TREATMENT OF CANCER AND BACTERIAL DISEASES
CA3156457A1 (en) 1,8-naphthyridin-2-one compounds for the treatment of autoimmune disease
EA200970745A1 (ru) Азабициклоалкановые производные, их получение и их применение в терапии